Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…